Skip to main content
Top
Published in: International Journal of Hematology 5/2021

01-05-2021 | Filgrastim | Original Article

Quality of life and patient-reported outcomes in chronic severe neutropenia conditions

Authors: Thomas F. Michniacki, Lauren E. Merz, Harlan McCaffery, James A. Connelly, Kelly Walkovich

Published in: International Journal of Hematology | Issue 5/2021

Login to get access

Abstract

Quality of life (QOL) and patient-reported outcomes (PROs) assessments in immunodeficiency patients, including those with chronic severe neutropenia conditions, are imperative to determining modifiable health-related features to optimize care. We present the largest study to date of QOL in those with chronic severe neutropenia conditions with further evaluation of patient provider satisfaction and patient-reported outcome measures. Subjects completed electronic surveys assessing QOL, PROs, and patient provider satisfaction. There is a significantly negative impact of a chronic severe neutropenia disorder on QOL, fatigue, physical function, cognitive function and pain in adult patients when compared to controls. Children with a chronic neutropenia condition had comparable QOL to controls, but reported fewer depressive symptoms, improved mobility, and stronger self-reported peer relationships. Adults had worse scores for QOL, depression and fatigue when compared to children. Adult and pediatric chronic severe neutropenia patients or their caregivers felt that their medical provider was compassionate, trustworthy, and accessible. However, less than 50% of adult patients agreed their clinician had excellent expertise in white blood cell disorders. Chronic neutropenia complexly affect QOL and PROs. An analysis of these parameters allows for targeted interventions to improve patient psychosocial, physical and neurocognitive health.
Literature
1.
go back to reference Quinti I, Pulvirenti F. Health-related quality of life and patients’ empowerment in the health care of primary immune deficiencies. J Clin Immunol. 2017;37:615–6.CrossRef Quinti I, Pulvirenti F. Health-related quality of life and patients’ empowerment in the health care of primary immune deficiencies. J Clin Immunol. 2017;37:615–6.CrossRef
2.
go back to reference Similuk MN, Wang A, Lenardo MJ, Erby LH. Life with a primary immune deficiency: a systematic synthesis of the literature and proposed research agenda. J Clin Immunol. 2016;36:123–33.CrossRef Similuk MN, Wang A, Lenardo MJ, Erby LH. Life with a primary immune deficiency: a systematic synthesis of the literature and proposed research agenda. J Clin Immunol. 2016;36:123–33.CrossRef
3.
go back to reference Peshko D, Kulbachinskaya E, Korsunskiy I, Kondrikova E, Pulvirenti F, Quinti I, et al. Health-related quality of life in children and adults with primary immunodeficiencies: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2019;7(1929–1957):e5. Peshko D, Kulbachinskaya E, Korsunskiy I, Kondrikova E, Pulvirenti F, Quinti I, et al. Health-related quality of life in children and adults with primary immunodeficiencies: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2019;7(1929–1957):e5.
4.
go back to reference Jones EA, Bolyard AA, Dale DC. Quality of life of patients with severe chronic neutropenia receiving long-term treatment with granulocyte colony-stimulating factor. JAMA. 1993;270:1132–3.CrossRef Jones EA, Bolyard AA, Dale DC. Quality of life of patients with severe chronic neutropenia receiving long-term treatment with granulocyte colony-stimulating factor. JAMA. 1993;270:1132–3.CrossRef
5.
go back to reference Fazio MT, Glaspy JA. The impact of granulocyte colony-stimulating factor on quality of life in patients with severe chronic neutropenia. Oncol Nurs Forum. 1991;18:1411–4.PubMed Fazio MT, Glaspy JA. The impact of granulocyte colony-stimulating factor on quality of life in patients with severe chronic neutropenia. Oncol Nurs Forum. 1991;18:1411–4.PubMed
6.
go back to reference Cleary PD, Morrissey G, Yver A, Oster G. The effects of rG-CSF on health-related quality of life in children with congenital agranulocytosis. Qual Life Res. 1994;3:307–15.CrossRef Cleary PD, Morrissey G, Yver A, Oster G. The effects of rG-CSF on health-related quality of life in children with congenital agranulocytosis. Qual Life Res. 1994;3:307–15.CrossRef
8.
go back to reference Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr. 2003;3:329–41.CrossRef Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr. 2003;3:329–41.CrossRef
10.
go back to reference Varni JW, Limbers CA. The PedsQL 4.0 generic core scales young adult version: feasibility, reliability and validity in a university student population. J Health Psychol. 2009;14:611–22.CrossRef Varni JW, Limbers CA. The PedsQL 4.0 generic core scales young adult version: feasibility, reliability and validity in a university student population. J Health Psychol. 2009;14:611–22.CrossRef
11.
go back to reference Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39:800–12.CrossRef Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39:800–12.CrossRef
12.
go back to reference Helgeson VS, Holmbeck GN. An introduction to the special issue on peer relations in youth with chronic illness. J Pediatr Psychol. 2015;40:267–71.CrossRef Helgeson VS, Holmbeck GN. An introduction to the special issue on peer relations in youth with chronic illness. J Pediatr Psychol. 2015;40:267–71.CrossRef
13.
go back to reference Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E, et al. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer. 2018;26:7–20.CrossRef Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E, et al. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer. 2018;26:7–20.CrossRef
14.
go back to reference Moore DC, Pellegrino AE. Pegfilgrastim-induced bone pain: a review on incidence, risk factors, and evidence-based management. Ann Pharmacother. 2017;51:797–803.CrossRef Moore DC, Pellegrino AE. Pegfilgrastim-induced bone pain: a review on incidence, risk factors, and evidence-based management. Ann Pharmacother. 2017;51:797–803.CrossRef
15.
go back to reference Fioredda F, Lanza T, Gallicola F, Riccardi F, Lanciotti M, Mastrodicasa E, et al. Long-term use of pegfilgrastim in children with severe congenital neutropenia: clinical and pharmacokinetic data. Blood. 2016;128:2178–81.CrossRef Fioredda F, Lanza T, Gallicola F, Riccardi F, Lanciotti M, Mastrodicasa E, et al. Long-term use of pegfilgrastim in children with severe congenital neutropenia: clinical and pharmacokinetic data. Blood. 2016;128:2178–81.CrossRef
16.
go back to reference Fioredda F, Calvillo M, Lanciotti M, Lanza T, Giunti L, Castagnola E, et al. Pegfilgrastim in children with severe congenital neutropenia. Pediatr Blood Cancer. 2010;54:465–7.CrossRef Fioredda F, Calvillo M, Lanciotti M, Lanza T, Giunti L, Castagnola E, et al. Pegfilgrastim in children with severe congenital neutropenia. Pediatr Blood Cancer. 2010;54:465–7.CrossRef
17.
go back to reference Dale DC, Bolyard AA, Schwinzer BG, Pracht G, Bonilla MA, Boxer L, et al. The severe chronic Neutropenia International Registry: 10-year follow-up report. Support Cancer Ther. 2006;3:220–31.CrossRef Dale DC, Bolyard AA, Schwinzer BG, Pracht G, Bonilla MA, Boxer L, et al. The severe chronic Neutropenia International Registry: 10-year follow-up report. Support Cancer Ther. 2006;3:220–31.CrossRef
18.
go back to reference Cheretakis C, Locker D, Dror Y, Glogauer M. Oral health-related quality of life of children with neutropenia. Spec Care Dent. 2007;27:6–11.CrossRef Cheretakis C, Locker D, Dror Y, Glogauer M. Oral health-related quality of life of children with neutropenia. Spec Care Dent. 2007;27:6–11.CrossRef
21.
go back to reference Pickett K, Loveman E, Kalita N, Frampton GK, Jones J. Educational interventions to improve quality of life in people with chronic inflammatory skin diseases: systematic reviews of clinical effectiveness and cost-effectiveness. Health Technol Assess. 2015;19(1–176):v–vi. Pickett K, Loveman E, Kalita N, Frampton GK, Jones J. Educational interventions to improve quality of life in people with chronic inflammatory skin diseases: systematic reviews of clinical effectiveness and cost-effectiveness. Health Technol Assess. 2015;19(1–176):v–vi.
22.
go back to reference Flanagan S, Damery S, Combes G. The effectiveness of integrated care interventions in improving patient quality of life (QoL) for patients with chronic conditions. An overview of the systematic review evidence. Health Qual Life Outcomes. 2017;15:188.CrossRef Flanagan S, Damery S, Combes G. The effectiveness of integrated care interventions in improving patient quality of life (QoL) for patients with chronic conditions. An overview of the systematic review evidence. Health Qual Life Outcomes. 2017;15:188.CrossRef
23.
go back to reference Grey M. Coping skills training for youths with diabetes. Diabetes Spectrum. 2011;24:70–5.CrossRef Grey M. Coping skills training for youths with diabetes. Diabetes Spectrum. 2011;24:70–5.CrossRef
24.
go back to reference Compas BE, Jaser SS, Dunn MJ, Rodriguez EM. Coping with chronic illness in childhood and adolescence. Annu Rev Clin Psychol. 2012;8:455–80.CrossRef Compas BE, Jaser SS, Dunn MJ, Rodriguez EM. Coping with chronic illness in childhood and adolescence. Annu Rev Clin Psychol. 2012;8:455–80.CrossRef
Metadata
Title
Quality of life and patient-reported outcomes in chronic severe neutropenia conditions
Authors
Thomas F. Michniacki
Lauren E. Merz
Harlan McCaffery
James A. Connelly
Kelly Walkovich
Publication date
01-05-2021
Publisher
Springer Singapore
Published in
International Journal of Hematology / Issue 5/2021
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-021-03089-8

Other articles of this Issue 5/2021

International Journal of Hematology 5/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine